NASDAQ: SPRBSpruce Biosciences Inc Stock
$110.10+2.85 (+2.66%)
Updated Oct 31, 2025
SPRB Price
$110.10
Fair Value Price
$74.87
Market Cap
$61.99M
52 Week Low
$4.28
52 Week High
$240.00
P/E
-1.28x
P/B
4.7x
P/S
2.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.30M
Earnings
-$48.34M
Gross Margin
100%
Operating Margin
-3,549.11%
Profit Margin
-3,721.2%
Debt to Equity
0.66
Operating Cash Flow
-$51M
Beta
1.41
Next Earnings
Nov 17, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SPRB Overview
Spruce Biosciences Incorporated develops and commercializes novel therapies for rare endocrine disorders. It is developing Tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from Congenital Adrenal Hyperplasia (CAH), which is in a Phase 2b clinical trial. Spruce Biosciences was incorporated in 2014 and is headquartered in Daly City, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRB's potential to beat the market
- SPRB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRB
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important SPRB news, forecast changes, insider trades & much more!
SPRB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRB ($110.10) is overvalued by 47.06% relative to our estimate of its Fair Value price of $74.87 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SPRB ($110.10) is not significantly undervalued (47.06%) relative to our estimate of its Fair Value price of $74.87 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRB due diligence checks available for Premium users.
Valuation
SPRB fair value
Fair Value of SPRB stock based on Discounted Cash Flow (DCF)
Price
$110.10
Fair Value
$74.87
Overvalued by
47.06%
SPRB ($110.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRB ($110.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.28x
Industry
-9.17x
Market
41.65x
SPRB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.7x
Industry
4.99x
SPRB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRB's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.1M
Profit Margin
0%
SPRB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SPRB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$21.8M
Liabilities
$8.6M
Debt to equity
0.66
SPRB's short-term assets ($20.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRB's short-term assets ($20.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPRB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.8M
Investing
$0.0
Financing
-$400.0k
SPRB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRB vs Biotech Stocks
Spruce Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.